{"anticipatedPostingDate":"2029-05","denomUnitsSelected":"Participants","description":"Outcome data will be provided after the study is completed.","reportingStatus":"NOT_POSTED","timeFrame":"Cycle 1 (28 days)","title":"Recommended LOXO-292 Dose for Phase 2 (MTD)","type":"SECONDARY"}